loading
Aldeyra Therapeutics Inc stock is traded at $4.81, with a volume of 1.51M. It is down -3.61% in the last 24 hours and up +22.39% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$4.99
Open:
$4.9
24h Volume:
1.51M
Relative Volume:
1.35
Market Cap:
$288.10M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.4133
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-6.96%
1M Performance:
+22.39%
6M Performance:
-8.21%
1Y Performance:
+29.65%
1-Day Range:
Value
$4.23
$4.92
1-Week Range:
Value
$4.23
$5.37
52-Week Range:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Name
Aldeyra Therapeutics Inc
Name
Phone
781-761-4904
Name
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Employee
8
Name
Twitter
@aldeyraaldx
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ALDX's Discussions on Twitter

Compare ALDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
4.81 298.88M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Upgrade Oppenheimer Perform → Outperform
Apr-02-24 Resumed H.C. Wainwright Buy
Apr-27-22 Resumed H.C. Wainwright Buy
Feb-08-21 Initiated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Oct-30-20 Initiated Jefferies Buy
Oct-16-20 Initiated BTIG Research Buy
Sep-22-20 Initiated Alliance Global Partners Buy
May-12-20 Initiated Oppenheimer Outperform
Dec-04-18 Initiated Citigroup Buy
Sep-26-18 Reiterated Cantor Fitzgerald Overweight
Sep-13-18 Initiated Janney Buy
Jan-26-18 Initiated Seaport Global Securities Buy
Sep-26-16 Initiated H.C. Wainwright Buy
Jul-01-16 Initiated Stifel Buy
Jul-01-15 Initiated Canaccord Genuity Buy
Mar-25-15 Initiated Chardan Capital Markets Buy
Mar-20-15 Reiterated H.C. Wainwright Buy
Nov-18-14 Initiated H.C. Wainwright Buy
Jun-19-14 Initiated Aegis Capital Buy
View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

pulisher
12:46 PM

Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - jammulinksnews.com

12:46 PM
pulisher
Aug 01, 2025

When is Aldeyra Therapeutics Inc. stock expected to show significant growthAdvanced Screener Growth Plan For Every Investor - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

What makes Aldeyra Therapeutics Inc. stock price move sharplyTop Growth Insights For Consistent Profits - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - jammulinksnews.com

Aug 01, 2025
pulisher
Jul 31, 2025

Exploring US High Growth Tech Stocks For July 2025 - simplywall.st

Jul 31, 2025
pulisher
Jul 31, 2025

Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Expert Picks Report For Fast Growth - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”Beginner Investor Data Feed For Every Investor - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 20:51:08 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Why did ALDX's EPS remain stagnant in recent quarters? - AInvest

Jul 29, 2025
pulisher
Jul 28, 2025

How does Aldeyra Therapeutics Inc. generate profit in a changing economyMarket Forecast Target Finder For 2025 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Aldeyra Therapeutics Inc. stock compared to the marketUnmatched market performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with explosive upside potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times

Jul 26, 2025
pulisher
Jul 25, 2025

Is Aldeyra Therapeutics Inc. a good long term investmentExplosive earning power - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan

Jul 24, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-23 18:29:07 - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare

Jul 18, 2025

Aldeyra Therapeutics Inc Stock (ALDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):